These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37168973)

  • 21. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
    Adams S; Diéras V; Barrios CH; Winer EP; Schneeweiss A; Iwata H; Loi S; Patel S; Henschel V; Chui SY; Rugo HS; Emens LA; Schmid P
    Ann Oncol; 2020 May; 31(5):582-589. PubMed ID: 32178964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer.
    Imanishi S; Morishima H; Gotoh T
    Jpn J Clin Oncol; 2022 Oct; 52(10):1167-1175. PubMed ID: 35766179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A Case of Breast Cancer Brain Metastases Successfully Treated with Pembrolizumab Therapy after Disease Progression with Atezolizumab Therapy].
    Hikino H; Otani A; Makino Y; Murata Y
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1456-1458. PubMed ID: 38303306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How I treat metastatic triple-negative breast cancer.
    Caparica R; Lambertini M; de Azambuja E
    ESMO Open; 2019; 4(Suppl 2):e000504. PubMed ID: 31231572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors.
    Di Spazio L; Rivano M; Cancanelli L; Chiumente M; Mengato D; Messori A
    Cureus; 2022 Jan; 14(1):e21065. PubMed ID: 35028245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).
    Saji S; Ohsumi S; Ito M; Hayashi N; Kobayashi K; Masuda N; Niikura N; Yamashita T; Kiyama K; Hasegawa A; Nakagawa S; Hattori M
    Jpn J Clin Oncol; 2022 Oct; 52(10):1124-1133. PubMed ID: 35750038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer.
    Ameri A; Tavakoli-Far B; Rostami M; Abedi Kiasari B; Sakhaei D; Saad Ahmed O; Forouzani F; Fazli Y
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109334. PubMed ID: 36327869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis.
    Qi Y; Yan X; Wang C; Cao H; Liu G
    Front Pharmacol; 2022; 13():1004821. PubMed ID: 36532783
    [No Abstract]   [Full Text] [Related]  

  • 32. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
    Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
    Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
    Kyte JA; Røssevold A; Falk RS; Naume B
    J Transl Med; 2020 Jun; 18(1):252. PubMed ID: 32576225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
    Cortés J; André F; Gonçalves A; Kümmel S; Martín M; Schmid P; Schuetz F; Swain SM; Easton V; Pollex E; Deurloo R; Dent R
    Future Oncol; 2019 Jun; 15(17):1951-1961. PubMed ID: 30977385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excellent response of refractory triple-negative breast cancer to sintilimab plus chemotherapy: a case report.
    Yao G; Huang J; Zhang Q; Hu D; Yuan F; Han G
    Immunotherapy; 2023 Mar; 15(4):221-228. PubMed ID: 36789554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility Study of Nanoparticle Albumin-Bound-Paclitaxel and S-1 Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer: A Prospective Study.
    Seki H; Higeta K; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
    Clin Breast Cancer; 2022 Apr; 22(3):235-243. PubMed ID: 34289949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study.
    Liu Y; Fan L; Wang ZH; Shao ZM
    Oncologist; 2023 Jan; 28(1):86-e76. PubMed ID: 36426808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
    Emens LA; Adams S; Barrios CH; Diéras V; Iwata H; Loi S; Rugo HS; Schneeweiss A; Winer EP; Patel S; Henschel V; Swat A; Kaul M; Molinero L; Patel S; Chui SY; Schmid P
    Ann Oncol; 2021 Aug; 32(8):983-993. PubMed ID: 34272041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
    Cortes J; Rugo HS; Cescon DW; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Perez-Garcia J; Iwata H; Masuda N; Torregroza Otero M; Gokmen E; Loi S; Guo Z; Zhou X; Karantza V; Pan W; Schmid P;
    N Engl J Med; 2022 Jul; 387(3):217-226. PubMed ID: 35857659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.